Analyzing Caladrius Biosciences (CLBS) & Its Peers

Caladrius Biosciences (NASDAQ: CLBS) is one of 184 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Caladrius Biosciences to similar businesses based on the strength of its earnings, valuation, dividends, risk, institutional ownership, profitability and analyst recommendations.

Earnings and Valuation

This table compares Caladrius Biosciences and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Caladrius Biosciences $35.28 million -$32.65 million -1.67
Caladrius Biosciences Competitors $217.29 million -$39.39 million -82.51

Caladrius Biosciences’ competitors have higher revenue, but lower earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings for Caladrius Biosciences and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caladrius Biosciences 0 0 1 0 3.00
Caladrius Biosciences Competitors 539 2388 6566 127 2.65

Caladrius Biosciences currently has a consensus price target of $7.00, indicating a potential upside of 102.90%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 19.90%. Given Caladrius Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Caladrius Biosciences is more favorable than its competitors.

Profitability

This table compares Caladrius Biosciences and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Caladrius Biosciences -84.10% -96.80% -43.98%
Caladrius Biosciences Competitors -4,713.12% -584.23% -45.87%

Insider and Institutional Ownership

6.4% of Caladrius Biosciences shares are owned by institutional investors. Comparatively, 47.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.1% of Caladrius Biosciences shares are owned by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Caladrius Biosciences has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Caladrius Biosciences’ competitors have a beta of 1.53, meaning that their average share price is 53% more volatile than the S&P 500.

Summary

Caladrius Biosciences beats its competitors on 8 of the 12 factors compared.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply